BOSTON SCIENTIFIC CORP (BSX.DE) Fundamental Analysis & Valuation
FRA:BSX • US1011371077
62 EUR
-1.2 (-1.9%)
Last: Mar 6, 2026, 07:00 PM
This BSX.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
Taking everything into account, BSX scores 5 out of 10 in our fundamental rating. BSX was compared to 63 industry peers in the Health Care Equipment & Supplies industry. While BSX belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. BSX shows excellent growth, but is valued quite expensive already. With these ratings, BSX could be worth investigating further for growth investing!.
1. BSX.DE Profitability Analysis
1.1 Basic Checks
- In the past year BSX was profitable.
- BSX had a positive operating cash flow in the past year.
- Each year in the past 5 years BSX has been profitable.
- BSX had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of 6.54%, BSX is in the better half of the industry, outperforming 71.43% of the companies in the same industry.
- BSX's Return On Equity of 11.93% is fine compared to the rest of the industry. BSX outperforms 69.84% of its industry peers.
- With a decent Return On Invested Capital value of 8.35%, BSX is doing good in the industry, outperforming 66.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.54% | ||
| ROE | 11.93% | ||
| ROIC | 8.35% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- BSX's Profit Margin of 14.42% is amongst the best of the industry. BSX outperforms 84.13% of its industry peers.
- In the last couple of years the Profit Margin of BSX has grown nicely.
- BSX has a better Operating Margin (19.40%) than 80.95% of its industry peers.
- In the last couple of years the Operating Margin of BSX has grown nicely.
- With a decent Gross Margin value of 68.57%, BSX is doing good in the industry, outperforming 74.60% of the companies in the same industry.
- BSX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 19.4% | ||
| PM (TTM) | 14.42% | ||
| GM | 68.57% |
OM growth 3Y6.45%
OM growth 5Y16.7%
PM growth 3Y41.81%
PM growth 5YN/A
GM growth 3Y-0.1%
GM growth 5Y1.06%
2. BSX.DE Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BSX is destroying value.
- There is no outstanding debt for BSX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- BSX has an Altman-Z score of 4.36. This indicates that BSX is financially healthy and has little risk of bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 4.36, BSX is in the better half of the industry, outperforming 77.78% of the companies in the same industry.
- BSX has a debt to FCF ratio of 3.03. This is a good value and a sign of high solvency as BSX would need 3.03 years to pay back of all of its debts.
- With a decent Debt to FCF ratio value of 3.03, BSX is doing good in the industry, outperforming 71.43% of the companies in the same industry.
- BSX has a Debt/Equity ratio of 0.48. This is a healthy value indicating a solid balance between debt and equity.
- BSX has a Debt to Equity ratio (0.48) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.48 | ||
| Debt/FCF | 3.03 | ||
| Altman-Z | 4.36 |
ROIC/WACC0.85
WACC9.79%
2.3 Liquidity
- BSX has a Current Ratio of 1.51. This is a normal value and indicates that BSX is financially healthy and should not expect problems in meeting its short term obligations.
- With a Current ratio value of 1.51, BSX perfoms like the industry average, outperforming 49.21% of the companies in the same industry.
- BSX has a Quick Ratio of 1.51. This is a bad value and indicates that BSX is not financially healthy enough and could expect problems in meeting its short term obligations.
- BSX has a Quick ratio of 0.96. This is comparable to the rest of the industry: BSX outperforms 41.27% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.51 | ||
| Quick Ratio | 0.96 |
3. BSX.DE Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an impressive 21.51% over the past year.
- Measured over the past years, BSX shows a very strong growth in Earnings Per Share. The EPS has been growing by 26.01% on average per year.
- The Revenue has grown by 19.88% in the past year. This is quite good.
- Measured over the past years, BSX shows a quite strong growth in Revenue. The Revenue has been growing by 15.16% on average per year.
EPS 1Y (TTM)21.51%
EPS 3Y20.34%
EPS 5Y26.01%
EPS Q2Q%14.29%
Revenue 1Y (TTM)19.88%
Revenue growth 3Y16.54%
Revenue growth 5Y15.16%
Sales Q2Q%15.9%
3.2 Future
- Based on estimates for the next years, BSX will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.13% on average per year.
- BSX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.46% yearly.
EPS Next Y14.83%
EPS Next 2Y14.13%
EPS Next 3Y13.68%
EPS Next 5Y13.13%
Revenue Next Year10.95%
Revenue Next 2Y10.73%
Revenue Next 3Y10.6%
Revenue Next 5Y10.46%
3.3 Evolution
- Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. BSX.DE Valuation Analysis
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 23.57, the valuation of BSX can be described as rather expensive.
- 60.32% of the companies in the same industry are more expensive than BSX, based on the Price/Earnings ratio.
- Compared to an average S&P500 Price/Earnings ratio of 26.29, BSX is valued at the same level.
- With a Price/Forward Earnings ratio of 20.57, BSX is valued on the expensive side.
- The rest of the industry has a similar Price/Forward Earnings ratio as BSX.
- BSX is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 24.57, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.57 | ||
| Fwd PE | 20.57 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, BSX is valued a bit more expensive than 61.90% of the companies in the same industry.
- BSX's Price/Free Cash Flow ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 27.94 | ||
| EV/EBITDA | 23.35 |
4.3 Compensation for Growth
- The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
- BSX has a very decent profitability rating, which may justify a higher PE ratio.
- BSX's earnings are expected to grow with 13.68% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.59
PEG (5Y)0.91
EPS Next 2Y14.13%
EPS Next 3Y13.68%
5. BSX.DE Dividend Analysis
5.1 Amount
- No dividends for BSX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
BSX.DE Fundamentals: All Metrics, Ratios and Statistics
FRA:BSX (3/6/2026, 7:00:00 PM)
62
-1.2 (-1.9%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-04 2026-02-04/bmo
Earnings (Next)04-21 2026-04-21/bmo
Inst Owners94.07%
Inst Owner ChangeN/A
Ins Owners0.15%
Ins Owner ChangeN/A
Market Cap91.95B
Revenue(TTM)20.07B
Net Income(TTM)2.79B
Analysts86
Price Target91.04 (46.84%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.27%
Min EPS beat(2)2.49%
Max EPS beat(2)4.06%
EPS beat(4)4
Avg EPS beat(4)5.68%
Min EPS beat(4)2.49%
Max EPS beat(4)10.56%
EPS beat(8)8
Avg EPS beat(8)6.15%
EPS beat(12)12
Avg EPS beat(12)5.77%
EPS beat(16)15
Avg EPS beat(16)4.37%
Revenue beat(2)2
Avg Revenue beat(2)1.69%
Min Revenue beat(2)0.96%
Max Revenue beat(2)2.43%
Revenue beat(4)4
Avg Revenue beat(4)1.6%
Min Revenue beat(4)0.96%
Max Revenue beat(4)2.43%
Revenue beat(8)8
Avg Revenue beat(8)2.16%
Revenue beat(12)11
Avg Revenue beat(12)2.08%
Revenue beat(16)13
Avg Revenue beat(16)1.61%
PT rev (1m)-16.43%
PT rev (3m)-18.09%
EPS NQ rev (1m)-0.01%
EPS NQ rev (3m)-0.01%
EPS NY rev (1m)0%
EPS NY rev (3m)0.12%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.04%
Revenue NY rev (1m)-0.44%
Revenue NY rev (3m)-0.44%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.57 | ||
| Fwd PE | 20.57 | ||
| P/S | 5.52 | ||
| P/FCF | 27.94 | ||
| P/OCF | 23.1 | ||
| P/B | 4.57 | ||
| P/tB | N/A | ||
| EV/EBITDA | 23.35 |
EPS(TTM)2.63
EY4.24%
EPS(NY)3.01
Fwd EY4.86%
FCF(TTM)2.22
FCFY3.58%
OCF(TTM)2.68
OCFY4.33%
SpS11.23
BVpS13.58
TBVpS-1.15
PEG (NY)1.59
PEG (5Y)0.91
Graham Number28.35
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.54% | ||
| ROE | 11.93% | ||
| ROCE | 10.04% | ||
| ROIC | 8.35% | ||
| ROICexc | 8.65% | ||
| ROICexgc | 29.1% | ||
| OM | 19.4% | ||
| PM (TTM) | 14.42% | ||
| GM | 68.57% | ||
| FCFM | 19.76% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y6.45%
OM growth 5Y16.7%
PM growth 3Y41.81%
PM growth 5YN/A
GM growth 3Y-0.1%
GM growth 5Y1.06%
F-Score6
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.48 | ||
| Debt/FCF | 3.03 | ||
| Debt/EBITDA | 2.18 | ||
| Cap/Depr | 59.36% | ||
| Cap/Sales | 4.14% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 90.6% | ||
| Profit Quality | 136.98% | ||
| Current Ratio | 1.51 | ||
| Quick Ratio | 0.96 | ||
| Altman-Z | 4.36 |
F-Score6
WACC9.79%
ROIC/WACC0.85
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.51%
EPS 3Y20.34%
EPS 5Y26.01%
EPS Q2Q%14.29%
EPS Next Y14.83%
EPS Next 2Y14.13%
EPS Next 3Y13.68%
EPS Next 5Y13.13%
Revenue 1Y (TTM)19.88%
Revenue growth 3Y16.54%
Revenue growth 5Y15.16%
Sales Q2Q%15.9%
Revenue Next Year10.95%
Revenue Next 2Y10.73%
Revenue Next 3Y10.6%
Revenue Next 5Y10.46%
EBIT growth 1Y30.66%
EBIT growth 3Y24.06%
EBIT growth 5Y34.39%
EBIT Next Year24.64%
EBIT Next 3Y16.7%
EBIT Next 5Y14.81%
FCF growth 1Y77.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y57.53%
OCF growth 3YN/A
OCF growth 5YN/A
BOSTON SCIENTIFIC CORP / BSX.DE FAQ
What is the ChartMill fundamental rating of BOSTON SCIENTIFIC CORP (BSX.DE) stock?
ChartMill assigns a fundamental rating of 5 / 10 to BSX.DE.
What is the valuation status for BSX stock?
ChartMill assigns a valuation rating of 3 / 10 to BOSTON SCIENTIFIC CORP (BSX.DE). This can be considered as Overvalued.
How profitable is BOSTON SCIENTIFIC CORP (BSX.DE) stock?
BOSTON SCIENTIFIC CORP (BSX.DE) has a profitability rating of 7 / 10.
What is the valuation of BOSTON SCIENTIFIC CORP based on its PE and PB ratios?
The Price/Earnings (PE) ratio for BOSTON SCIENTIFIC CORP (BSX.DE) is 23.57 and the Price/Book (PB) ratio is 4.57.
Can you provide the expected EPS growth for BSX stock?
The Earnings per Share (EPS) of BOSTON SCIENTIFIC CORP (BSX.DE) is expected to grow by 14.83% in the next year.